Johnson & Johnson indicated good levels of AI investment, with the company looking for 969 new artificial intelligence jobs since October 2020. Credit: Michael Vi / Shutterstock.com

Novartis and Johnson & Johnson are among the companies best positioned to take advantage of future artificial intelligence disruption in the pharmaceuticals industry, our analysis shows.

The assessment comes from GlobalData’s Thematic Research ecosystem, which ranks companies on a scale of one to five based on their likelihood to tackle challenges like artificial intelligence and emerge as long-term winners of the pharmaceuticals sector.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to our analysis, Novartis, Johnson & Johnson, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline and Bayer are the companies best positioned to benefit from investments in artificial intelligence, all of them recording scores of five out of five in GlobalData’s Drug Development Thematic Scorecard.

Novartis, for example, has advertised for 327 new artificial intelligence jobs from October 2020 to September 2021, has completed one deal related to artificial intelligence with other companies and mentioned artificial intelligence in company filings 10 times.

Johnson & Johnson indicated good levels of AI investment, with the company looking for 969 new artificial intelligence jobs since October 2020 and mentioning artificial intelligence in filings 30 times.

The table below shows how GlobalData analysts scored the biggest companies in the pharmaceuticals industry on their artificial intelligence performance, as well as the number of new artificial intelligence jobs, deals, patents and mentions in company reports since October 2020.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Higher numbers usually indicate that a company has spent more time and resources on improving its artificial intelligence performance, or that artificial intelligence is at least at the top of executives’ minds. However, it may not always mean that it is doing better than the competition.

A high number of mentions of artificial intelligence in quarterly company filings could indicate either that the company is reaping the rewards of previous investments, or that it needs to invest more to catch up with the rest of the industry. Similarly, a high number of deals could indicate that a company is dominating the market, or that it is using mergers and acquisitions to fill in gaps in its offering.

Nevertheless, these trends are useful in showing us the extent to which top executives in the pharmaceuticals sector – and at specific organisations – think about artificial intelligence, and the extent to which they stake their future on it.

This article is based on GlobalData research figures as of 10 November 2021. For more up-to-date figures, check the GlobalData website.